micromobility.com Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that micromobility.com Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $1.42M | Apr 15, 2025 |
| FY2023 | Dec 31, 2023 | $9.84M | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | $15.54M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $12.83M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $4.42M | Apr 15, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $8.15M | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | ($62.06M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($82.07M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($71.97M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($24.57M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($627.2K) | May 21, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($2.30M) | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | ($19.94M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($73.50M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($59.12M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($19.94M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($107.9K) | May 21, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2023 | $1.95M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $2.74M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $2.83M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $1.60M | Apr 15, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($8.51M) | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | ($37.47M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($43.10M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($42.99M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($11.41M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($56.8K) | May 21, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $2.14M | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $7.03M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $41.15M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $53.62M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $6.36M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $58.10M | May 21, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $35.30M | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $50.83M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $80.06M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $61.47M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $17.67M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $3.16M | May 21, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($33.16M) | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | ($43.80M) | Apr 15, 2025 |
| FY2024 | Dec 31, 2022 | ($39.85M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2021 | ($7.85M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2020 | ($15.35M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2019 | ($10.00M) | Apr 15, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2022 | $13.83M | Apr 16, 2024 |
| FY2023 | Dec 31, 2021 | $10.70M | Apr 16, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($243.21M) | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | ($252.00M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($189.94M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($108.68M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($36.22M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($627.2K) | May 21, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $84.0K | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $67.0K | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $429.0K | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $21.14M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $757.0K | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $471.3K | May 21, 2021 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $51.88M | Apr 15, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | (42) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | (9,360) | Apr 16, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | (42) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | (9,360) | Apr 16, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | 2.25M | May 21, 2021 |
| FY2020 | Dec 31, 2019 | 2.20M | May 21, 2021 |